Table 2.

Association between ten SNPs in RNASEL and prostate cancer, stratified by Gleason score

SNP rs#	Best-fitting model	Minor allele frequency, controls N = 1267	Minor allele frequency, cases with Gleason score ≤ (3 +4) N = 1102	OR (95% CI)	Minor allele frequency, cases with Gleason score ≥ (4 +3) N = 202	OR (95% CI)	Nominal p-value†
rs12723593	Trend	0.29	0.32	1.14 (1.00 – 1.28)	0.31	1.10 (0.88 – 1.39)	0.82
rs635261	Trend	0.38	0.36	0.92 (0.81 – 1.03)	0.37	0.96 (0.77 – 1.19)	0.70
rs12729828	Dominant	0.14	0.16	1.10 (0.91 – 1.32)	0.14	0.93 (0.65 – 1.31)	0.34
rs627839	Dominant	0.45	0.48	1.15 (0.96 – 1.38)	0.49	1.19 (0.85 – 1.68)	0.84
rs11807829	Dominant	0.34	0.32	0.91 (0.77 – 1.07)	0.32	0.85 (0.63 – 1.15)	0.67
rs627928	Recessive	0.44	0.45	1.19 (0.99 – 1.44)	0.47	1.06 (0.75 – 1.51)	0.53
rs486907	Dominant	0.37	0.36	0.91 (0.77 – 1.08)	0.33	0.72 (0.53 – 0.98)	0.13
rs56250729	Dominant	0.007	0.01	1.82 (1.00 – 3.31)	0.01	1.86 (0.68 – 5.07)	0.97
Gly59Ser (no rs#)	Dominant	0.008	< 0.01	0.62 (0.29 – 1.33)	< 0.01	0.32 (0.04 – 2.44)	0.54
rs682585	Dominant	0.38	0.39	1.07 (0.91 – 1.27)	0.41	1.08 (0.79 – 1.47)	0.98

Note: Four cases for whom Gleason score is unknown were excluded from stratified analyses.

OR: Odds ratio adjusted for 5-year age groups; CI: Confidence Interval;

^†p-value is Chi square test with 1 degree of freedom, testing the difference between risk estimates for lower- vs. higher-Gleason score groups.